Gilde Healthcare's Private Equity fund sells majority stake in European CRO/CDMO Symeres to Keensight Capital
Keensight Capital, one of the principal private equity managers dedicated to pan-European Growth Buyout1 investments, has reached an agreement to invest alongside management in Symeres, a leading European drug discovery Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO).
According to the terms of the agreement, Keensight Capital will acquire a majority stake in Symeres from the Gilde Healthcare Private Equity fund, a leading European specialist healthcare investor.
Sandrine LekkerkerkerAssociate Tax lawyer
Sandrine Lekkerkerker, tax lawyer, is a member of the International Tax Services practice group in our Amsterdam office. She focuses on Dutch corporate tax and Tax M&A and is a member of the Tax M&A team.T: +31 20 578 58 75 M: +31 683 20 33 47 E: email@example.com